Ultime notizie per ATAI Life Sciences (NASDAQ:ATAI) Azioni

ATAI Life Sciences

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

ATAI Life Sciences NV

Researchers from Emory University, the University of Wisconsin-Madison and UC-Berkeley have identified a significant opportunity for <a href="https://www.benzinga.com/topic/psilocybin-assisted-therapy">psilocybin-assisted therapy</a> in the U.S. mental healthcare landscape. As U.S. News <a href="https://www.usnews.com/news/health-news/articles/2024-09-13/over-5-million-americans-could-benefit-if-psilocybin-approved-for-depression-study">reported</a>, if approved by the <a href="https://www.benzinga.com/topic/food-and-drug-administration">FDA</a>, psilocybin could be used to treat depression, with an estimated 5.1 to 5.6 million Americans potentially benefiting from the therapy.
Examining a group of patients undergoing treatment for depression, researchers determined that psilocybin could be a game-changing solution, particularly for individuals suffering from major depressive disorder (MDD) or treatment-resistant depression (TRD). These conditions, which affect millions across the country, are typically unresponsive to standard treatments, underscoring the urgent need for new solutions.
<h3 class="wp-block-heading">A Breakthrough Approach To Treating Depression</h3>
The study, <a href="https://pp.genomicpress.com/wp-content/uploads/2024/09/PP0025-Rab-2024.pdf">published</a> in Psychedelics by Genomic Press, explored the FDA's consideration of psilocybin from <a href="https://www.benzinga.com/markets/cannabis/22/11/29549541/the-strongest-magic-mushroom-species">Psilocybe cubensis</a> mushrooms as a <a href="https://www.benzinga.com/general/biotech/24/03/37665900/fda-grants-cybin-breakthrough-therapy-status-for-major-depression-psilocybin-therapy-company-anno">breakthrough therapy,</a> which is a designation that allows drugs with the potential to address life-threatening conditions like severe depression, to be fast-tracked through the approval process. If green-lighted, psilocybin would likely be reserved for individuals with the most severe forms of depression or those who have not responded to traditional treatments.
The study found that some 1.7 million Americans with TRD could immediately benefit from psilocybin-assisted therapy. When including those with MDD, the number of potential beneficiaries rises to 5.6 million. Dr. Syed Fayzan Rab, an MD candidate at Emory University and the study's lead author, highlighted the importance of recognizing the scope of this opportunity. "This underscores the importance of understanding the practical realities of rolling out this novel treatment on a large scale."
<h3 class="wp-block-heading">A Market Ready To Take Off</h3>
Implications of this study go beyond healthcare. The psilocybin-assisted therapy market holds immense economic potential. A 2023 <a href="https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1293243/full">report</a> estimated that a single psilocybin-assisted therapy session could cost around $1,500 per patient. Considering the millions of individuals who may be eligible for treatment, this could translate into billions of dollars in revenue once psilocybin gains FDA approval.
Several companies are already preparing to capitalize on this potential market. Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>), Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) and Mindset Pharma (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MSSTF#OTC">MSSTF</a>) are among the pharmaceutical firms actively developing psilocybin-based treatments. 
<h3 class="wp-block-heading">Beyond Depression: Psilocybin's Expanding Horizon</h3>
While psilocybin's most immediate application lies in depression treatment, its therapeutic potential extends further. Ongoing studies are investigating psilocybin's efficacy in treating chronic pain and <a href="https://www.benzinga.com/topic/ptsd">post-traumatic stress disorder</a>. These developments signal that psilocybin could revolutionize not just mental healthcare but also the treatment of other chronic conditions.
However, psilocybin remains classified as a <a href="https://www.benzinga.com/topic/controlled-substances-act">Schedule I</a> drug at the federal level, meaning it is considered to have no accepted medical use and a high potential for abuse. This classification, shared with substances like marijuana, heroin and <a href="https://www.benzinga.com/topic/lsd">LSD</a>, complicates the path toward legalizing its medical use. 
Despite these federal restrictions, several U.S. states and local jurisdictions have <a href="https://www.benzinga.com/topic/psychedelics-decriminalization">decriminalized psilocybin</a> in recent years, signaling a growing push for policy reform at higher levels. 
"It's our hope that these findings spur productive discussions and proactive preparations to optimize the benefit to patients while minimizing unintended consequences," said Dr. Charles Raison, a professor of psychiatry at the University of Wisconsin and co-author of the study. 
Cover image made with AI

Cannabis

News

Psychedelics

Regulations

Health Care

ATAI

CMPS

MSSTF

Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes

Psychedelics have shown promise in treating various mental health issues, including <a href="https://www.benzinga.com/topic/ptsd">PTSD</a> and depression, but they&#8217;ve often faced notable challenges. Side effects like nausea, cardiovascular risks, and the potential for "bad trips" have raised concerns among both clinicians and patients. As Time <a href="https://time.com/7027173/new-psychedelic-drug-companies/">reported</a>, companies like Mindstate Design Labs and Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) are developing new forms of psychedelics, sometimes called Psychedelics 2.0, designed to offer therapeutic benefits with fewer risks.
<h3 class="wp-block-heading">Challenges And Limitations Of Traditional Psychedelics</h3>
Traditional psychedelics like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a>, <a href="https://www.benzinga.com/topic/mdma">MDMA</a> and <a href="https://www.benzinga.com/topic/lsd">LSD</a> work by <a href="https://www.benzinga.com/markets/cannabis/23/02/30965404/delix-elucidating-how-psychedelics-actually-induce-neuroplasticity-vs-ssris">promoting neuroplasticity</a>, which helps the brain form new connections and process trauma. However, these substances can be time-intensive, sometimes requiring patients to endure hours-long sessions under medical supervision. This protocol not only strains mental health resources but can also be daunting for patients.
Dillan DiNardo, CEO of <a href="https://www.benzinga.com/topic/mindstate-design-labs">Mindstate Design Labs</a>, describes classic psychedelics as "effective, but they're scary and unpredictable." His company aims to refine psychedelics to retain their mental health benefits while minimizing adverse effects. These novel drugs may also ease the burden on the mental health system, as the reduced risk could potentially allow for fewer monitoring requirements.
The FDA recently <a href="https://www.benzinga.com/markets/cannabis/24/08/40300943/fda-rejects-mdma-for-ptsd-treatment-calls-for-more-research-on-psychedelic-therapy">withheld approval of MDMA for PTSD treatment</a>, citing concerns over potential heart risks and the need for constant monitoring. Dr. Srinivas Rao, co-CEO of Atai Life Sciences, explains that these challenges have encouraged companies to find safer alternatives. One such development is <a href="https://www.benzinga.com/general/biotech/24/03/37973466/pharmalas-novel-mdma-mixture-awarded-us-patent-enabling-ip-protection-and-further-development">R-MDMA</a>, which offers a more introspective experience with fewer side effects.
<h3 class="wp-block-heading">Rethinking Psychedelic Therapy</h3>
Companies like Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) are taking a different approach by attempting to strip psychedelics of their hallucinogenic effects altogether. Enveric's CEO Joseph Tucker suggests that a <a href="https://www.benzinga.com/markets/cannabis/22/12/30007837/tripping-without-the-trip-non-hallucinogenic-psychedelics">non-hallucinogenic version of psychedelics</a>, if effective, could function much like an antidepressant, providing relief without the need for extensive in-clinic sessions.
This approach has its critics, however, with some researchers arguing that the psychedelic experience itself is essential to therapeutic progress. Studies suggest that feelings of connectedness, common in psychedelic experiences, are linked to improved mental health outcomes.
<h3 class="wp-block-heading">Selective Psychedelics: Targeted Effects For Improved Safety</h3>
Mindstate Design Labs is exploring ways to create psychedelics with more targeted effects on the brain. DiNardo likens psychedelics to "promiscuous molecules" that influence various neural pathways. By honing in on specific effects, Mindstate seeks to reduce the chaotic nature of traditional psychedelics and make the treatment experience more predictable.
<h3 class="wp-block-heading">The Future Of Psychedelic Therapy</h3>
While these developments offer promising solutions, the path to FDA approval and widespread acceptance remains complex. Whether future psychedelics can provide mental health benefits without the downsides of traditional compounds will depend on ongoing research and clinical trials. As DiNardo notes, "psychedelics do not work for everyone in a positive way." But with advances in Psychedelics 2.0, companies seem to be optimistic about creating more patient-friendly therapies for mental health challenges.
Cover image made with AI

ENVB

Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies

The U.S. Food and Drug Administration (FDA) has issued a complete response letter for <a href="https://www.benzinga.com/topic/mdma-assisted-therapy">MDMA-assisted psychotherapy (MDMA-AT)</a> for treating post-traumatic stress disorder (PTSD) in which it calls for an additional phase 3 trial to further evaluate its safety and efficacy. As Psychiatric Times <a href="https://www.psychiatrictimes.com/view/with-mdma-on-hold-whats-next-for-psychedelics">reported</a>, this decision puts on hold what could have been a landmark approval for the treatment of PTSD with MDMA, also known as midomafetamine.
Despite the <a href="https://www.benzinga.com/markets/cannabis/24/08/40300943/fda-rejects-mdma-for-ptsd-treatment-calls-for-more-research-on-psychedelic-therapy">setback</a>, <a href="https://www.benzinga.com/topic/lykos-therapeutics">Lykos Therapeutics</a>, the company behind the MDMA-AT treatment, remains determined. Lykos has expressed confidence that the FDA's concerns could be addressed using "existing data, post-approval requirements or through reference to the scientific literature." Discussions between the company and the FDA are ongoing, as Lykos seeks a clear path forward.
<h3 class="wp-block-heading">Other Psychedelics In The Pipeline</h3>
While MDMA's future remains in question, several other psychedelic treatments continue to progress through clinical trials. Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) recently announced promising results from a <a href="https://www.benzinga.com/markets/cannabis/24/08/40376236/atais-dmt-depression-drug-shows-promise-prepares-for-phase-ii-trial-and-future-collaboration-wit">phase 1b trial of VLS-01</a>, a buccal film formulation of N,N-dimethyltryptamine (DMT), for treatment-resistant depression (TRD). The next phase 2 study is expected to start by the end of 2024, focusing on safety, efficacy and durability of response.
Numinus Wellness (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTC">NUMIF</a>), another key player in the psychedelic space, is <a href="https://www.benzinga.com/markets/cannabis/23/11/35548014/single-dose-of-cybins-psilocybin-shows-compelling-patient-outcomes-phase-2-results-find">moving forward with studies</a> involving Cybin's CYB003, a deuterated psilocybin molecule designed for treating moderate to severe depressive disorders. Meanwhile, Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) is testing COMP360, a synthetic form of psilocybin, which <a href="https://www.benzinga.com/markets/cannabis/23/09/34291309/compass-pathways-explores-ai-powered-predictive-model-on-psilocybin-therapy-for-depression">has shown promising early results</a> in treating PTSD. These developments highlight the continued push toward psychedelic-assisted therapies for a range of psychiatric conditions.
<h3 class="wp-block-heading">Progress With LSD And Ketamine</h3>
MindBio Therapeutics (NASDAQU:MBIO) has also made strides with MB22001, <a href="https://www.benzinga.com/markets/cannabis/24/04/38512570/lsd-microdosing-for-pms-after-confirming-antidepressant-effects-clinical-trials-will-assess-if-i">a titratable microdosing form of LSD</a>, showing promise in phase 2a trials for major depressive disorder (MDD). They are investigating LSD's potential for treating other conditions like premenstrual dysphoric disorder and depression associated with cancer. MindMed is <a href="https://www.benzinga.com/markets/cannabis/22/08/28637136/mindmed-keeps-hitting-the-news-now-dosing-on-their-clinical-trial-on-lsd-for-anxiety">progressing with its own LSD compound</a>, MM-120, which has shown potential for treating generalized anxiety disorder (GAD), with a phase 3 trial set to begin this year.
Ketamine-based therapies are advancing as well, with Awakn Life Sciences (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AWAKNF#OTC">AWAKNF</a>) leading the charge in <a href="https://www.benzinga.com/markets/cannabis/23/06/32820420/awakn-to-focus-on-r-d-of-addiction-therapies-moves-away-from-ketamine-treatment-for-alcoholism">addressing alcohol use disorder</a>. Their MORE-KARE phase 3 trial is underway, testing the efficacy of ketamine infusions combined with psychosocial support.
<h3 class="wp-block-heading">Lykos And The Future Of MDMA</h3>
As the psychedelic field expands, all eyes are on Lykos Therapeutics as they navigate the FDA&#8217;s requirements for MDMA-assisted psychotherapy. The company has undergone a <a href="https://www.benzinga.com/markets/cannabis/24/08/40421048/lykos-therapeutics-strategic-reorganization-following-fdas-decision-rejecting-mdma-for-ptsd-trea">significant reorganization</a>, including a 75% reduction in workforce, and appointed Dr. David Hough as senior medical advisor to guide the next phase of clinical work. Hough has extensive experience in psychiatric drug development, having led successful projects such as Spravato.
Rick Doblin, PhD, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), has stepped down from Lykos to focus on public advocacy for global access to MDMA and other psychedelics. Doblin&#8217;s resignation from the Lykos Board comes as the company continues its dialogue with the FDA.
<h3 class="wp-block-heading">What's Next?</h3>
Despite the challenges facing <a href="https://www.benzinga.com/topic/mdma-assisted-therapy">MDMA-assisted psychotherapy</a>, the field of psychedelic research remains vibrant. With more than 185 clinical studies on psilocybin, 104 on MDMA and 58 on LSD ongoing according to clinicaltrials.gov, the future holds promise for these novel treatments. As companies continue their work, patients and researchers alike are hopeful that these therapies will become more widely available in the near future.
Cover image made with AI

AWAKNF

MBIO

NUMIF

MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?

The global <a href="https://www.benzinga.com/markets/psychedelics">psychedelic drugs</a> market is poised for significant growth over the next five years, with an estimated increase of USD 1.37 billion from 2024 to 2028, according to a <a href="https://www.prnewswire.com/news-releases/psychedelic-drugs-market-to-grow-by-usd-1-37-billion-from-2024-2028--driven-by-increasing-mental-health-disorders-report-highlights-ais-impact-on-the-market-landscape---technavio-302236016.html">report</a> by Technavio. The market is projected to grow at a compound annual growth rate (CAGR) of 11.82%, fueled by the rising prevalence of mental health disorders and the development of next-generation therapies for psychiatric conditions.
<h3 class="wp-block-heading">Expanding Market For Psychedelics In Mental Health</h3>
Increasing awareness of the <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">therapeutic potential</a> of psychedelic substances, such as <a href="https://www.benzinga.com/topic/ketamine">ketamine</a>, <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a>, and <a href="https://www.benzinga.com/topic/mdma">MDMA</a>, has spurred investment in research and development. These substances have shown promise in treating disorders like treatment-resistant depression, PTSD, narcolepsy and addiction. The market is also witnessing a trend towards AI-driven advancements in the understanding and development of psychedelic therapies.
However, regulatory challenges and potential side effects associated with psychedelic drugs present obstacles to market growth. Many substances remain classified as <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule I</a> drugs, creating barriers to widespread availability, especially in hospital and retail pharmacies.
<h3 class="wp-block-heading">Major Players And Market Segments</h3>
Key players in the psychedelic drugs market include AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>), COMPASS Pathways (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Mind Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>). These companies are at the forefront of developing safe and effective psychedelic therapies for mental health conditions.
The market is segmented by type, including ketamine, GHB, MDMA and psilocybin. Distribution channels such as hospital pharmacies, retail pharmacies and others play a critical role in the accessibility of these therapies. Geographically, North America, Europe, Asia and the rest of the world (ROW) are identified as major regions driving growth.
<h3 class="wp-block-heading">AI's Role In Shaping The Psychedelic Drugs Market</h3>
<a href="https://www.benzinga.com/topic/artificial-intelligence">Artificial intelligence</a> is becoming an essential tool in drug development and market evolution, helping companies streamline research, clinical trials, and product development. By integrating AI, firms can accelerate the creation of targeted therapies and better understand the complex interactions between psychedelic drugs and mental health conditions.
<h3 class="wp-block-heading">Market Challenges And Ethical Concerns</h3>
Despite its growth potential, the psychedelic drugs market faces significant challenges, including regulatory scrutiny and ethical concerns. The potential for misuse and psychological distress associated with psychedelic substances, especially in forms like injectable or intranasal psilocybin, remains a concern. Cultural norms, conservative values, and religious beliefs also influence the pace of adoption in various regions.
<h3 class="wp-block-heading">Future Outlook</h3>
As companies continue to push forward with clinical trials and product development, the market for psychedelic drugs is expected to expand significantly. The anticipated approval of new psychedelic-based therapies, coupled with AI-driven innovations, holds promise for addressing the global mental health crisis. However, overcoming regulatory and cultural barriers will be critical to unlocking the full potential of this emerging field.

Press Releases

ABBV

COMP

MNMD

Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Buy and maintains $15 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target

Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) announced promising preliminary results on Tuesday for its DMT-based depression therapy, <a href="https://www.benzinga.com/markets/cannabis/23/10/35070268/atai-life-sciences-completes-phase-1-clinical-study-of-oral-film-dmt-formulation">VLS-01</a>. As BioSpace <a href="https://www.biospace.com/drug-development/atai-touts-early-data-on-psychedelic-depression-drug-plans-phase-ii-trial">reported</a>, these findings from a Phase Ib study position Atai to move forward with a Phase II trial later this year, targeting patients with <a href="https://www.benzinga.com/topic/treatment-resistant-depression">treatment-resistant depression</a>.
<h3 class="wp-block-heading">Promising Phase Ib Results For DMT-Based Depression Therapy</h3>
VLS-01, an oral formulation of <a href="https://www.benzinga.com/topic/dmt">N,N-dimethyltryptamine (DMT)</a>, is designed to be administered via a buccal film applied to the lining of the cheek. This delivery method aims to induce a short, controlled psychedelic experience, potentially offering relief to those suffering from treatment-resistant depression. The active ingredient is different from other psychedelic therapies, such as <a href="https://www.benzinga.com/topic/lykos-therapeutics">Lykos Therapeutics'</a> MDMA, which was <a href="https://www.benzinga.com/markets/cannabis/24/08/40300943/fda-rejects-mdma-for-ptsd-treatment-calls-for-more-research-on-psychedelic-therapy">recently rejected by the FDA</a>, or <a href="https://www.benzinga.com/topic/compass-pathways">Compass Pathways'</a> psilocybin treatments, VLS-01 provides a unique approach to addressing mental health challenges, say company officials.
<h3 class="wp-block-heading">The Phase Ib Study</h3>
The research involved 17 healthy volunteers, who received a single intravenous dose of DMT followed by three different doses of the buccal formulation, administered 28 days apart. The study aimed to compare the safety, tolerability, pharmacokinetics and pharmacodynamics of the buccal film to the intravenous form. The results were encouraging, with the two higher doses (120mg and 160mg) achieving peak plasma concentrations comparable to the intravenous dose.
Atai <a href="https://www.globenewswire.com/news-release/2024/08/13/2929035/0/en/atai-Life-Sciences-Announces-Positive-Preliminary-Results-from-Phase-1b-Trial-of-VLS-01-Buccal-Film-DMT.html">reported</a> &#8220;dose-dependent and robust subjective effects&#8221; at these higher doses, with 13 out of 14 participants scoring greater than 7 out of 10 on the Subjective Intensity Rating Scale at the 120mg dose. The effects were noted to resolve completely after two hours, with participants describing the experience as &#8220;psychologically meaningful&#8221; and highlighting an increase in &#8220;levels of self-reflection.&#8221;
<h3 class="wp-block-heading">Safety Profile And Next Steps</h3>
The safety profile of VLS-01 was another positive outcome of the study. The most common treatment-emergent adverse events (TEAEs) reported were headache, dissociation, euphoric mood, and nausea. All adverse events were mild or moderate and resolved on the day of dosing, with no reports of vomiting or local irritation at doses of 120mg or less. Only one participant reported nausea at the 120mg dose, and there were no incidents of suicidality.
Building on these results, Atai has <a href="https://clinicaltrials.gov/study/NCT06524830">filed to conduct a Phase II</a> trial by the end of 2024, which will compare VLS-01 to a placebo in 142 patients with treatment-resistant depression. This study will evaluate the efficacy, safety, and durability of repeated doses of VLS-01 in patients with TRD, and is expected to provide topline data by the end of 2025.
<h3 class="wp-block-heading">Strategic Positioning And Future Outlook</h3>
"We're delighted with the positive results from the VLS-01 Phase 1b study, which further support its potential as a promising therapeutic option for the 100 million people worldwide suffering from treatment-resistant depression," said Dr. Srinivas Rao, co-CEO and co-founder of Atai.
Atai's strategic approach to developing a psychedelic that can be administered within a two-hour clinic visit could align it with existing infrastructure used for administering <a href="https://www.benzinga.com/topic/johnson-johnson">Johnson &amp; Johnson's</a> ketamine-based depression drug, <a href="https://www.benzinga.com/markets/cannabis/24/07/39913847/pharma-giant-johnson-johnson-asks-fda-to-approve-esketamine-nasal-spray-for-treatment-resistant-">Spravato</a>. 
Atai co-CEO Florian Brand, speaking at H.C. Wainwright's Neuro Perspectives Conference in June 2024, highlighted the potential to leverage the &#8220;very compelling infrastructure&#8221; established by Spravato&#8217;s more than 4,000 certified clinics. &#8220;With [J&amp;J] now guiding to achieve beyond a billion of sales this year, we believe we have a very compelling infrastructure that we can leverage with this compound,&#8221; Brand said.
Cover image made with AI

Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant

Guidance

atai Life Sciences Expects Cash, Marketable Securities, And Committed Term Loan Funding To Fund Operations Into 2026

Earnings

atai Life Sciences Q2 EPS $(0.36), Down From $(0.21) Last Year; License Revenue $273K, Up From $172K Prior Year

In a historic move for the psychedelics industry, PATOO, a Jamaica-based psychedelic consumer packaged goods (CPG) brand, has announced a partnership with Fontana Pharmacy, the island's leading pharmacy chain with more than 500 employees across 7 locations, <a href="https://www.benzinga.com/cannabis">Benzinga</a> has learned exclusively. This landmark collaboration introduces the first legal psilocybin-infused products to Jamaican pharmacy shelves, marking a significant step toward broader acceptance and accessibility of psychedelic wellness products.
<h2 class="wp-block-heading">Psychedelics At The Pharmacy? A Reality In Jamaica</h2>
&#8220;Jamaica has evolved into a sanctuary for those pursuing inner healing, and we are honored to offer our meticulously crafted products as alternative plant-based remedies to consumers. We prioritize safety and quality, rigorously testing each batch to ensure the utmost standards,&#8221; said Kevin Bourke, co-founder of PATOO.
Products include microdose capsules, handcrafted microdose honey, premium chocolate bars and vegan psilocybin gummies, all presented in childproof packaging to prevent underage consumption and ensure responsible use. 
Each batch of psilocybin products is rigorously tested to ensure the highest quality and safety standards, as emphasized by the commitment of PATOO and their partnership with Fontana Pharmacy. This includes adhering to local regulatory guidelines and ensuring product safety for consumers.
<h2 class="wp-block-heading">Psilocybin&#8217;s Global Presence: Legal Status And Access</h2>
Netherlands: In the Netherlands, psilocybin truffles have found a legal niche, despite psilocybin mushrooms being illegal. This loophole allows psilocybin truffles to be sold legally in &#8220;Smart Shops&#8221; across the country, providing a model for how psychedelics can be integrated into a retail environment under specific regulatory frameworks​.
Australia: Australia recently made headlines by allowing the prescription of psilocybin for certain psychiatric conditions such as PTSD and treatment-resistant depression. This regulatory change followed extensive clinical trials and approval from the Therapeutic Goods Administration (TGA). These prescriptions are tightly controlled and monitored, ensuring safe and effective use for medical purposes​.
Canada: In Canada, psilocybin can be accessed through the Special Access Program (SAP) for medical purposes, particularly for end-of-life distress, PTSD and depression. The approval process involves stringent applications and oversight by Health Canada, reflecting the country's cautious yet progressive stance on psychedelic therapy​.
<h2 class="wp-block-heading">The Jamaican Framework: A Model Of Controlled Access</h2>
Jamaica's approach to psilocybin is unique, given its historical tolerance and evolving regulatory landscape. Unlike the prescription-only models seen in Australia and Canada, Jamaica allows broader retail distribution of psilocybin products under controlled conditions. The Jamaican government actively promotes the country as a destination for psychedelic research and development, with interim protocols ensuring the safety and quality of psilocybin products​.
Products are stored securely behind the counter, and all retail displays and educational materials are labeled with age restrictions and safe use instructions. Staff at Fontana locations have undergone thorough training on dosage, benefits and safety measures, ensuring informed and responsible use by consumers, a PATOO spokesperson told Benzinga.
<h2 class="wp-block-heading">Broader Implications And Future Prospects</h2>
The introduction of psilocybin products into Jamaican pharmacies is more than a commercial achievement, it is a testament to the growing acceptance and integration of psychedelics into mainstream wellness practices. Jamaica, along with the Netherlands, Australia and Canada, is at the forefront of this movement, setting a precedent for other nations considering similar regulatory changes.
&#8220;We believe that PATOO's meticulously crafted products provide safe and effective plant-based alternatives for wellness, and we are excited to make these groundbreaking solutions accessible across Jamaica,&#8221; said Bourke. 
As the landscape of psychedelic wellness continues to evolve, the successful integration of psilocybin products into pharmacies in Jamaica and other forward-thinking nations offers a promising blueprint for the future. 
<h2 class="wp-block-heading">Key Publicly Traded Companies In The Psychedelics Industry</h2>
Several publicly traded companies are at the forefront of developing and commercializing psychedelic therapies, contributing to the growing legitimacy and acceptance of psychedelic treatments. Here are some notable companies:
<ul>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>): Specializes in psilocybin-based therapies for treatment-resistant depression.</li>
<li>Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>): Focuses on a portfolio of psychedelic substances, including psilocybin, through various partnerships and collaborations​.</li>
<li>Cybin Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>): Developing multiple psilocybin therapies for conditions like major depressive disorder and alcohol use disorder​​.</li>
<li>Mind Medicine (MindMed) Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>): Engages in psychedelic and plant-based therapies for mental health conditions such as anxiety and substance abuse​.</li>
<li>Mydecine Innovations Group Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MYCOF#OTC">MYCOF</a>): A life sciences company focused on developing psychedelic medicine and natural health products, with several clinical trials underway.</li>
<li>Seelos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>): Working on treatments for CNS disorders using ketamine and psilocybin​.</li>
<li>Revive Therapeutics Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RVVTF#OTC">RVVTF</a>): Researching psilocybin-based therapeutics for various mental health conditions​.</li>
<li>Havn Life Sciences (CSE:<a class="ticker" href="https://www.benzinga.com/stock/HAVN#CSE">HAVN</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HAVLF#OTC">HAVLF</a>): Engages in the research and development of natural health products and psychedelic compounds.</li>
<li>Red Light Holland (CSE:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#CSE">TRIP</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TRUFF#OTC">TRUFF</a>): Distributes legal recreational psilocybin truffles in the Netherlands​.</li>
</ul>
These companies are leading the charge in the development of psilocybin therapies, contributing to a broader acceptance of psychedelics in medical and wellness contexts.
Stay tuned to <a href="https://www.benzinga.com/cannabis">Benzinga</a> for more developments in the psychedelics industry.

Exclusives

CSE:HAVN

CSE:TRIP

CYBN

HAVLF

MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC.

MYCOF

RVVTF

SEEL

TRIP

RED LIGHT HOLLAND CORP by Red Light Holland Corp.

TRUFF

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves

Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on ATAI Life Sciences

<ul>
<li>ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours.</li>
<li>The Phase 2a part of the study will evaluate the safety, tolerability, subjective effects, and efficacy of a single intravenous (IV) dose of ELE-101 in 6-12 participants with Major Depressive Disorder (MDD). Results are expected in H2 2024.</li>
<li>The dose for Phase 2a was selected using preliminary pharmacokinetic (PK) and pharmacodynamic (PD) data from the Phase 1 randomized, double-blind, placebo-controlled, single ascending dose part of the study of ELE-101 in healthy participants, which showed that it was well-tolerated with no serious adverse events. ELE-101 showed a dose-proportional PK profile and a reliable induction of short-duration psychedelic experiences.</li>
</ul>

Biotech

General

Atai Life Sciences Announced An Update On Beckley Psytech's Phase 1/2A Trial Of ELE-101 For Major Depressive Disorder, With Initial Results From Phase 1 And The Dosing Of The First Patients In The Phase 2A Part Of The Study

A panel of advisors to the Food and Drug Administration (FDA) <a href="https://www.benzinga.com/markets/cannabis/24/06/39175839/fda-panel-rejects-mdma-therapy-for-ptsd-citing-concerns-over-research-data-in-setback-for-advoca">rejected MDMA as a treatment </a>for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling. The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues. Some members of the panel, like sociologist Elizabeth Joniak-Grant, pointed to allegations of misconduct in trials that could have skewed results as a reason for voting against the use of MDMA in PTSD patients, according to <a href="https://www.npr.org/sections/shots-health-news/2024/06/04/nx-s1-4991112/mdma-therapy-ptsd-fda-advisors">NPR. </a>Read Also: <a href="https://www.benzinga.com/news/24/06/39186971/whats-going-on-with-mindmed-and-psychedelic-stocks">What&#8217;s Going On With MindMed And Psychedelic Stocks?</a>
Market Movers: Many stocks in the psychedelic space traded lower Wednesday following the ruling. Cybin Inc (NYSEAMERICAN:CYBN), which develops drugs and treatments derived from psychedelic substances like psilocybin, was down by more than 10% Wednesday afternoon. Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>), another biotech using psychedelic substances as a derivative for its treatments, traded lower by more than 8% Wednesday. ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) opened Wednesday's trading session down more than 14% from its closing price Tuesday, but was able to recover some of its losses throughout Wednesday's session, and last traded down around 6%. The AdvisorShares Psychedelics ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSIL#NYSE">PSIL</a>), a fund that tracks many publicly traded psych stocks, traded around 6% lower Wednesday afternoon. 
What's Next: While the FDA does not have to follow that advisory board's recommendation, the ruling was seen throughout the industry as a blow to the progress made in approving and regulating treatments that utilize psychedelics. Proponents of psych drugs argue that many show more effectiveness than mental health treatments currently available on the market. 
Now Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39192058/nvidia-has-multi-year-lead-on-amd-intel-bank-of-america-analyst-expects-stock-to-hi">Nvidia Has &#8216;Multi-Year Lead&#8217; On AMD, Intel: Bank Of America Analyst Expects Stock To Hit $1,500 Per Share</a>
Photo: Shutterstock

Specialty ETFs

Movers

ETFs

PSIL

Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment

Mind Medicine (MindMed) Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with <a href="https://www.benzinga.com/news/24/06/39181909/douyu-international-posts-q1-results-joins-annexon-dollar-tree-and-other-big-stocks-moving-lower-in">post-traumatic stress disorder (PTSD).</a>
The Details:
MindMed and other psychedelic stocks, including ATAI Life Sciences N.V (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) and COMPASS Pathways Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>), are down after an FDA panel rejected the use of MDMA-assisted therapy for PTSD on Tuesday.
The FDA panel voted 9 to 2 on whether the MDMA-assisted therapy was effective and 10 to 1 on whether the proposed treatment's benefits outweighed its risks. Members of the panel expressed concerns about the designs of the two studies submitted by Lykos Therapeutics, including study participants correctly identifying MDMA versus the placebo.&nbsp;&nbsp;
The FDA's rejection of the Lykos Therapeutics drug highlights the regulatory issues faced by companies developing psychedelic therapies and treatments.&nbsp;
Related News: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39172163/wedbushs-dan-ives-says-wwdc-2024-is-most-important-event-for-apple-in-over-a-decade">Wedbush&#8217;s Dan Ives Says WWDC 2024 Is &#8216;Most Important Event For Apple In Over A Decade&#8217;: What To Expect</a>
<h2 class="wp-block-heading">Will MNMD Stock Go Up?</h2>
When trying to assess whether or not Mind Medicine will trade higher from current levels, it's a good idea to take a look at analyst forecasts. 
Wall Street analysts have an average 12-month price target of $33.75 on Mind Medicine. The Street high target is currently at $75 and the Street low target is $20. Of all the analysts covering Mind Medicine, 8 have positive ratings, no one has neutral ratings and no one has negative ratings.
In the last month, 4 analysts have adjusted price targets. Here's a look at recent price target changes <a href="https://www.benzinga.com/quote/MNMD/analyst-ratings">[Analyst Ratings]</a>. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering Mind Medicine have performed in recent history. 
Stocks don't move in a straight line. The average stock market return is approximately 10% per year. Mind Medicine is 86.33% up year-to-date. The average analyst price target suggests the stock could have further upside ahead.
For a broad overview of everything you need to know about Mind Medicine, visit <a href="https://www.benzinga.com/quote/MNMD">here</a>. If you want to go above and beyond, there's no better tool to help you do just that than <a href="https://pro.benzinga.com/">Benzinga Pro</a>. Start your free trial today.
MNMD, ATAI, CMPS Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, MindMed shares are down 15% at $7.00, Atai Life Sciences shares are down 6.55% at $1.43 and Compass Pathways shares are down 11.5% at $6.78 at the time of publication Wednesday.
Image: Shutterstock

What's Going On With MindMed And Psychedelic Stocks?

WIIM

GHRS

Shares of psychedelics companies are trading lower after an FDA panel, on Tuesday, rejected the approval of MDMA therapy for people with PTSD.

ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 19.05 percent increase over losses of $(0.21) per share from the same period last year.

ATAI Life Sciences Q1 EPS $(0.17) Beats $(0.18) Estimate, Cash $18.87M

Florida-based cannabis company Kaya Holdings Inc ., AKA KAYS, (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTCQB">KAYS</a>) has been awarded a license by the Oregon Health Authority to operate a Psilocybin Service Center.
Oregon is the only state in the US that has developed a licensing framework that allows for the administration of psilocybin in a safe and legal setting under the guidance of State Licensed Facilitators. KAYS through its Fifth Dimension Therapeutics, Inc. subsidiary, plans to operate The Sacred Mushroom, a full-service psychedelic treatment center that will allow clients to receive psilocybin treatment in a setting offering significant experience differentiators and concept innovations. The Sacred Mushroom expects to service its first guests within the next thirty days.  
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/23/01/30572011/this-cannabis-company-will-soon-provide-legal-psychedelics-assisted-therapy" target="_blank" rel="noreferrer noopener">This Cannabis Company Will Soon Provide Legal Psychedelics-Assisted Therapy</a>
&#8220;The introduction of legal psilocybin treatments in Oregon marks the beginning of perhaps the most disruptive force in the mental health sector, transforming treatment protocol and redirecting resources,&#8221; stated KAYS CEO&nbsp;Craig Frank.&nbsp;&#8220;Our distinctive guest experience model, the environment offered by the&nbsp;size and design of the facility and the dedication of our staff&nbsp;are designed to make The Sacred Mushroom the premier choice for anyone turning to psychedelics for relief or transformation.&nbsp;For these reasons, I believe KAYS is well positioned to become a leader in the ‘delivery of care&#8217; of psychedelics.&#8221;
Cannabis and psychedelics sectors sometimes fuse, being similar in terms of both offering natural compounds to help treat various ailments. If you want to learn more about the future of the cannabis industry, join us at the Benzinga Cannabis Capital Conference this October in Chicago. Hear directly from key industry players and policymakers. Get your tickets now by following&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.&nbsp;
Located on the top floor of the historic Falcon Building in downtown Portland and spread over approximately 11,000 square feet, The Sacred Mushroom will offer guests &#8220;room to roam,&#8221;unsurpassed comfort, optional private rooms, activity zones with yoga, listening stations, journaling chairs and art expression. There will also be a &#8220;sensation room,&#8221; indoor garden and customized experience through its proprietary Synergy By Design &#8220;your setting, your way&#8221; program.
Psilocybin, a naturally occurring compound found in &#8220;magic mushrooms,&#8221; is one of an emerging class of psychedelic medicines that contain potent psychoactive chemicals that can affect human perception, emotions and other cognitive functions. Recent university medical studies have shown psilocybin treatment to be a potentially effective treatment path for people suffering from trauma, PTSD, depression, anxiety disorders, addictions and other hard-to-treat mental health conditions.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/04/38504261/experts-discuss-botanical-psilocybins-effect-on-neurogenesis-and-more-at-benzinga-cannabis-confe" target="_blank" rel="noreferrer noopener">Experts Discuss Botanical Psilocybin&#8217;s Effect On Neurogenesis And More At Benzinga Cannabis Conference</a>
Companies such as&nbsp;Compass Pathways&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>),&nbsp;ATAI Life Sciences&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>), and&nbsp;Cybin&nbsp;(AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#AMEX">CYBN</a>) are engaged in developing synthetic versions of psilocybin and psilocin (the active ingredient in &#8220;magic mushrooms&#8221;) to offer as alternative therapies for treatment-resistant mental health disorders. Delivery of these synthetic psilocybin options, when available, is expected to be administered at licensed psychedelic treatment centers such as The Sacred Mushroom.
<h2 class="wp-block-heading">Price Action&nbsp;</h2>
Kaya Holdings closed Wednesday market session 9.38% lower at $0.043 per share.&nbsp;
Photo: Courtesy of KAYS

KAYS

Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon

Atai Life Sciences Disclosed Dosing Of First Patient In Part 2 Of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive To SSRIs In Patients With Treatment Resistant Depression

Jim Cramer recently hyped up one of his guests in advance of his CNBC show "Mad Money," posting on X that people "will be very interested in MindMed for certain &#8230; LSD," and he made sure his interview did not disappoint.
Mind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) sees a massive market opportunity ahead, citing 21% of U.S. adults with an anxiety disorder, an estimated 4.4% of U.S. adults with attention-deficit/hyperactivity disorder (ADHD) and a $461 billion economic cost from autism spectrum disorder by 2025.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/zette">Anyone can invest in this Harvard-founded AI startup</a> solving paywalls and growing 5x yearly by partnering with Forbes, Daily News and more.</li>
<li>Invest alongside execs from Uber, Facebook and Apple in this<a href="https://www.benzinga.com/money/aura"> wellness app Transforming a $5.6 TRILLION dollar industry</a>.</li>
</ul>
While the conditions they're seeking to treat are not new, MindMed's plan to treat patients with LSD and MDMA-derived therapies could be described as unconventional.
But its story has gained investors' attention. MindMed shares have had an impressive run this year, with its stock up over 167% year to date.
One reason for the stock's recent jump was the Food and Drug Administration's (FDA) decision to grant breakthrough designation for MindMed's LSD-based treatment for generalized anxiety disorder.
<a href="https://www.benzinga.com/topic/mindmed">MindMed</a> Chief Medical Officer Dr. Daniel Karlin described the achievement, saying, "A breakthrough designation is a recognition that a drug has demonstrated evidence of clinical efficacy in meeting an unmet medical need" and called it "an offer from the agency to engage more closely in drug development."
Trending: Invest like a millionaire. Exclusive opportunity to<a href="https://www.benzinga.com/money/epic-games"> invest in Epic Games $17 billion gaming empire.</a>
Following the interview, Cramer suggested that scientific advances in psychedelics-based therapy are taking a backseat to political agendas, posting on X that "<a href="https://t.co/OfcgQY7TtX">Mindmed.com</a> intrigued me because it is pretty clear that the LSD-derived antidepressants were blocked politically and criminalized after good tests showing they worked!!!"
MindMed reported results from its phase IIB trial of its MM-120 drug, an LSD-derived therapy, which showed a 78% clinical response against anxiety versus just 31% for a placebo.
Only "transient mild-to-moderate" adverse effects were reported, with none of the study's participants in even the highest trial doses stopping the trial because of side effects.
"These promising findings represent a major step forward in our goal to bring a paradigm-shifting treatment to the millions of patients who are profoundly impacted by GAD [generalized anxiety disorder]," MindMed CEO Robert Barrow said.&nbsp;
MindMed's shares still have a long way to go to get back to its 2021 peak, with the stock down nearly 84% since then.
The stocks of other companies developing psychedelic-derived therapies, such as ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) and Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>), also remain well off their peaks.
Keep Reading <a href="https://www.benzinga.com/alternative-investments/startups">About Startups</a>:
<ul>
<li>This startup coined &#8220;eBay for gamers&#8221; with a breathtaking track record has opened up<a href="https://www.benzinga.com/money/gameflip-2"> a window to invest in its future growth</a>.</li>
<li>Join the elite. Invest in Epic Games and<a href="https://www.benzinga.com/money/epic-games"> own a piece of the $17 billion Fortnite empire</a>.</li>
</ul>

Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'

Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report

Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past week.

Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on ATAI Life Sciences (ATAI – Research Report) today and set a price target of $15...

Buy Rating Affirmed for ATAI Life Sciences Amid Progress in Neurology Pipeline and Potential Market Opportunities

Psychedelic Stock Deep Dive: Atai Life Sciences

The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a Portfolio of the 4 largest such companies.

Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August

Undercovered Dozen: EPR Properties, Gilead, Portland General Electric, CNH Industrial +

While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are having growing pains.

Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th

The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.

Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week

Warning: ATAI is at high risk of performing badly

Bright Minds rally ends as psychedelic stocks extend volatility

ATNF

BAMXF

BMWYY

BYMOF

CLFD

CMND

DRUG

GILD

MMDCF

NTSGF

SATS

SPRC

Screenshot 2024-05-21 at 6.46.56 PM

SILO

FTRP

Revolutionizing Mental Healthcare With The Rise Of Ketamine And Psychedelic Therapies

Management

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

atai Life Sciences co-CEO says initial results from ELE-101 show promise in treating depression

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Comments

ATAI Life Sciences

Notizie

Ultime notizie per ATAI Life Sciences (NASDAQ:ATAI) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO